{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:37:02Z","timestamp":1787002622201,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T00:00:00Z","timestamp":1408406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1038\/nrrheum.2014.139","type":"journal-article","created":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T08:53:18Z","timestamp":1408438398000},"page":"752-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Screening for hyperuricaemia and gout: a perspective and research agenda"],"prefix":"10.1038","volume":"10","author":[{"given":"Lisa","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,19]]},"reference":[{"key":"BFnrrheum2014139_CR1","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","volume":"46","author":"N Dalbeth","year":"2007","unstructured":"Dalbeth, N.  et al. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford) 46, 1804\u20131807 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014139_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/RHU.0b013e3181b562f8","volume":"15","author":"I Hutton","year":"2009","unstructured":"Hutton, I., Gamble, G., Gow, P. & Dalbeth, N. Factors associated with recurrent hospital admissions for gout: a case-controlled study. J. Clin. Rheumatol. 15, 271\u2013274 (2009).","journal-title":"J. Clin. Rheumatol."},{"key":"BFnrrheum2014139_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/epirev\/mxr005","volume":"33","author":"R Harris","year":"2011","unstructured":"Harris, R., Sawaya, G., Moyer, V. & Calonge, N. Reconsidering the criteria for evaluating proposed screening programmes: reflections from 4 current and former members of the U. S. Preventive Services Task Force. Epidemiol. Rev. 33, 20\u201335 (2011).","journal-title":"Epidemiol. Rev."},{"key":"BFnrrheum2014139_CR4","volume-title":"Principles and practice of screening for disease","author":"JMG Wilson","year":"1968","unstructured":"Wilson, J. M. G. & Jungner, G. Principles and practice of screening for disease (WHO, Geneva, 1968)."},{"key":"BFnrrheum2014139_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1136\/annrheumdis-2014-205304","volume":"73","author":"N Dalbeth","year":"2014","unstructured":"Dalbeth, N. & Stamp, L. Hyperuricaemia and gout: time for a new staging system? Ann. Rheum. Dis. 73, 1598\u20131600 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014139_CR6","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"D Feig","year":"2008","unstructured":"Feig, D., Kang, H.-R. & Johnson, R. Uric acid and cardiovascular risk. N. Engl. J. Med. 359, 1811\u20131821 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2014139_CR7","doi-asserted-by":"publisher","first-page":"f4262","DOI":"10.1136\/bmj.f4262","volume":"347","author":"T Palmer","year":"2013","unstructured":"Palmer, T.  et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. BMJ 347, f4262 (2013).","journal-title":"BMJ"},{"key":"BFnrrheum2014139_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/ki.2013.353","volume":"85","author":"K Hughes","year":"2013","unstructured":"Hughes, K., Flynn, T., de Zoysa, J., Dalbeth, N. & Merriman, T. Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function. Kidney Int. 85, 344\u2013351 (2013).","journal-title":"Kidney Int."},{"key":"BFnrrheum2014139_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu, Y., Pandya, B. & Choi, H. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am. J. Med. 125, 679\u2013687 (2012).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2014139_CR10","doi-asserted-by":"publisher","first-page":"f5648","DOI":"10.1136\/bmj.f5648","volume":"347","author":"E Roddy","year":"2013","unstructured":"Roddy, E. & Mallen, C. Gout. BMJ 347, f5648 (2013).","journal-title":"BMJ"},{"key":"BFnrrheum2014139_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2011.154997","volume":"71","author":"E De Miguel","year":"2012","unstructured":"De Miguel, E.  et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann. Rheum. Dis. 71, 157\u2013158 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014139_CR12","doi-asserted-by":"publisher","unstructured":"Sun, Y.  et al. Features of urate deposition in patients with gouty arthritis of the foot using dual-energy computed tomography. Int. J. Rheum. Dis. \n                    http:\/\/dx.doi.org\/10.1111\/1756-185X.12194\n                    \n                  .","DOI":"10.1111\/1756-185X.12194"},{"key":"BFnrrheum2014139_CR13","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/rheumatology\/kes147","volume":"51","author":"G Jackson","year":"2012","unstructured":"Jackson, G.  et al. Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. Rheumatology (Oxford) 51, 1820\u20131824 (2012).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014139_CR14","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1093\/rheumatology\/ket154","volume":"52","author":"N Dalbeth","year":"2013","unstructured":"Dalbeth, N.  et al. New classification criteria for gout: a framework for progress. Rheumatology (Oxford) 52, 1748\u20131753 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014139_CR15","doi-asserted-by":"publisher","unstructured":"Richette, P.  et al. Identification of patients with gout: elaboration of a questionnaire for epidemiological studies. Ann. Rheum. Dis. \n                    http:\/\/dx.doi.org\/10.1136\/annrheumdis-2013-204976\n                    \n                  .","DOI":"10.1136\/annrheumdis-2013-204976"},{"key":"BFnrrheum2014139_CR16","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna, D.  et al. 2012 American College of Rheumatology guidelines for the management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia. Arthritis Care Res. (Hoboken) 64, 1431\u20131446 (2012).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2014139_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","volume":"82","author":"E Campion","year":"1987","unstructured":"Campion, E., Glynn, R. & DeLabry, L. Asymptomatic hyperuricaemia: risks and consequence in the normative aging study. Am. J. Med. 82, 421\u2013426 (1987).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2014139_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"J Kanis","year":"2008","unstructured":"Kanis, J., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385\u2013397 (2008).","journal-title":"Osteoporos. Int."},{"key":"BFnrrheum2014139_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","volume":"121","author":"K Anderson","year":"1991","unstructured":"Anderson, K., Odell, P., Wilson, P. & Kannel, W. Cardiovascular disease risk profiles. Am. Heart J. 121, 293\u2013298 (1991).","journal-title":"Am. Heart J."},{"key":"BFnrrheum2014139_CR20","doi-asserted-by":"publisher","unstructured":"De Vera, M., Marcotte, G., Rai, S., Galo J. & Bhole, V. Medication adherence in gout: a systematic review. Arthritis Care Res. (Hoboken) \n                    http:\/\/dx.doi.org\/10.1002\/acr.22336\n                    \n                  .","DOI":"10.1002\/acr.22336"},{"key":"BFnrrheum2014139_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/106002809302700317","volume":"27","author":"F Arellano","year":"1993","unstructured":"Arellano, F. & Sacristan, J. Allopurinol hypersensitivity syndrome: a review. Ann. Pharmacother. 27, 337\u2013343 (1993).","journal-title":"Ann. Pharmacother."},{"key":"BFnrrheum2014139_CR22","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1148\/radiol.2323031095","volume":"232","author":"D Brenner","year":"2004","unstructured":"Brenner, D. & Elliston, C. Estimated radiation risks potentially associated with full-body CT screening. Radiology 232, 735\u2013738 (2004).","journal-title":"Radiology"},{"key":"BFnrrheum2014139_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1378\/chest.13-1420","volume":"145","author":"R McCunney","year":"2014","unstructured":"McCunney, R. & Li, J. Radiation risks in lung cancer screening programs: a comparison with nuclear industry workers and atomic bomb survivors. Chest 145, 618\u2013624 (2014).","journal-title":"Chest"},{"key":"BFnrrheum2014139_CR24","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/rheumatology\/kem150","volume":"46","author":"E Roddy","year":"2007","unstructured":"Roddy, E., Zhang, W. & Doherty, M. Is gout associated with reduced quality of life? A case controlled study. Rheumatology (Oxford) 46, 1441\u20131444 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014139_CR25","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","volume":"52","author":"P Chandratre","year":"2013","unstructured":"Chandratre, P.  et al. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford) 52, 2031\u20132040 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014139_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1471-2261-12-108","volume":"12","author":"VC Kok","year":"2012","unstructured":"Kok, V. C.  et al. Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan. BMC Cardiovasc. Disord. 12, 108 (2012).","journal-title":"BMC Cardiovasc. Disord."},{"key":"BFnrrheum2014139_CR27","unstructured":"Calonge, N. Screening populations for those at-risk for future disease: promises and pitfalls. Presented at the American College of Rheumatology Annual Meeting, San Diego, 2013."},{"key":"BFnrrheum2014139_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.semarthrit.2010.09.003","volume":"40","author":"L Stamp","year":"2011","unstructured":"Stamp, L.  et al. Serum urate as a soluble biomarker in chronic gout\u2014evidence that serum urate fulfils the OMERACT validation criteria for soluble biomarkers. Semin. Arthritis Rheum. 40, 483\u2013500 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum2014139_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/art.1780150209","volume":"15","author":"J Loeb","year":"1972","unstructured":"Loeb, J. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 15, 189\u2013192 (1972).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.139","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:34:16Z","timestamp":1684456456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2014.139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,19]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["BFnrrheum2014139"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2014.139","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,19]]},"assertion":[{"value":"19 August 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.S. declares she has received consulting fees from AstraZeneca. N.D. declares she has received consulting or speaker fees from Takeda, Savient, Menorini, AstraZeneca, Ardea, Novartis, Metabolex and Fonterra.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}